TY - JOUR
T1 - Implementing a Machine-Learning-Adapted Algorithm to Identify Possible Transthyretin Amyloid Cardiomyopathy at an Academic Medical Center
AU - Mitchell, Joshua
AU - Lenihan, Daniel
AU - Reed, Casey
AU - Huda, Ahsan
AU - Nolen, Kim
AU - Bruno, Marianna
AU - Kannampallil, Thomas
N1 - Funding Information:
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: JD Mitchell has received research funding from Longer Life Foundation and Children’s Discovery Institute in addition to receiving research support for this study from Pfizer. He has also received modest consulting fees from Pfizer to present the results of this study. DJ Lenihan reports research funding from Myocardial Solutions, and consulting fees from AstraZeneca, Clementia, Eidos, and Prothena. T Kannampallil has received research support from the Agency for Healthcare Research and Quality, the National Institutes of Health, and Pfizer. C Reed, A Huda, K Nolen, and M Bruno are full-time employees of Pfizer and hold Pfizer stock and/or stock options.
Publisher Copyright:
© The Author(s) 2022.
PY - 2022
Y1 - 2022
N2 - Background: Wild-type transthyretin amyloid cardiomyopathy (ATTR-CM) is a frequently under-recognized cause of heart failure (HF) in older patients. To improve identification of patients at risk for the disease, we initiated a pilot program in which 9 cardiac/non-cardiac phenotypes and 20 high-performing phenotype combinations predictive of wild-type ATTR-CM were operationalized in electronic health record (EHR) configurations at a large academic medical center. Methods: Inclusion criteria were age >50 years and HF; exclusion criteria were end-stage renal disease and prior amyloidosis diagnoses. The different Epic EHR configurations investigated were a clinical decision support tool (Best Practice Advisory) and operational/analytical reports (Clarity™, Reporting Workbench™, and SlicerDicer); the different data sources employed were problem list, visit diagnosis, medical history, and billing transactions. Results: With Clarity, among 45 051 patients with HF, 4006 patients (8.9%) had ⩾1 phenotype combination associated with increased risk of wild-type ATTR-CM. Across all data sources, 2 phenotypes (cardiomegaly; osteoarthrosis) and 2 combinations (carpal tunnel syndrome + HF; atrial fibrillation + heart block + cardiomegaly + osteoarthrosis) generated the highest proportions of patients for wild-type ATTR-CM screening. Conclusion: All EHR configurations tested were capable of operationalizing phenotypes or phenotype combinations to identify at-risk patients; the Clarity report was the most comprehensive.
AB - Background: Wild-type transthyretin amyloid cardiomyopathy (ATTR-CM) is a frequently under-recognized cause of heart failure (HF) in older patients. To improve identification of patients at risk for the disease, we initiated a pilot program in which 9 cardiac/non-cardiac phenotypes and 20 high-performing phenotype combinations predictive of wild-type ATTR-CM were operationalized in electronic health record (EHR) configurations at a large academic medical center. Methods: Inclusion criteria were age >50 years and HF; exclusion criteria were end-stage renal disease and prior amyloidosis diagnoses. The different Epic EHR configurations investigated were a clinical decision support tool (Best Practice Advisory) and operational/analytical reports (Clarity™, Reporting Workbench™, and SlicerDicer); the different data sources employed were problem list, visit diagnosis, medical history, and billing transactions. Results: With Clarity, among 45 051 patients with HF, 4006 patients (8.9%) had ⩾1 phenotype combination associated with increased risk of wild-type ATTR-CM. Across all data sources, 2 phenotypes (cardiomegaly; osteoarthrosis) and 2 combinations (carpal tunnel syndrome + HF; atrial fibrillation + heart block + cardiomegaly + osteoarthrosis) generated the highest proportions of patients for wild-type ATTR-CM screening. Conclusion: All EHR configurations tested were capable of operationalizing phenotypes or phenotype combinations to identify at-risk patients; the Clarity report was the most comprehensive.
KW - Cardiac amyloidosis
KW - electronic health record
KW - identification
KW - machine learning
KW - transthyretin amyloidosis
UR - http://www.scopus.com/inward/record.url?scp=85142908545&partnerID=8YFLogxK
U2 - 10.1177/11795468221133608
DO - 10.1177/11795468221133608
M3 - Article
C2 - 36386406
AN - SCOPUS:85142908545
SN - 1179-5468
VL - 16
JO - Clinical Medicine Insights: Cardiology
JF - Clinical Medicine Insights: Cardiology
ER -